Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Advanced Solid Tumor 1

Interventions

pembrolizumab 33Injections 28Pemetrexed 15Interviews as Topic 15Carboplatin 14tislelizumab 13Cisplatin 13Specimen Handling 12Bevacizumab 11atezolizumab 10Nivolumab 10Practice Guidelines as Topic 9Educational Status 9Cyclophosphamide 9Standard of Care 8Oxaliplatin 8Fluorouracil 8fludarabine 7Methods 7Early Intervention, Educational 7Docetaxel 7Cetuximab 7Capecitabine 7toripalimab 6sotorasib 6Paclitaxel 6Leucovorin 6olaparib 5Platinum 5Ipilimumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Antineoplastic Agents × Other solid neoplasm × 90 days × Clear all
NCT06625593 2026-05-29

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
168 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡